7. 大脳皮質基底核変性症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 16 / 薬物数 : 28 - (DrugBank : 13) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 38
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
18F-AV-1451
Skåne University Hospital, Region Skåne
2014 - EUCTR2014-000422-38-SE Sweden;
18F-FDG
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036908 Japan;
18F-RO6958948
Skåne University Hospital
2017 Phase 2 EUCTR2017-000094-36-SE Sweden;
ABBV-8E12
AbbVie
2018 - NCT03744546 -
Anti-Parkinson medication
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Apomorphine
Fondation Ophtalmologique Adolphe de Rothschild
2018 - NCT04786158 France;
BIIB092
University of California, San Francisco
2018 Phase 1 NCT03658135 United States;
Brain PET scan
Avid Radiopharmaceuticals
2014 Phase 1 NCT02167594 United States;
Davunetide (AL-108, NAP)
University of California, San Francisco
2010 Phase 1 NCT01056965 United States;
Deep Brain Stimulation
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Dopamine
Juntendo University school of MedicineDepartment of Diagnosis, Prevention and Treatment of Dementia
2014 - JPRN-UMIN000014098 Japan;
Fasudil
Woolsey Pharmaceuticals
2021 Phase 2 NCT04734379 United States;
Flortaucipir F18
Avid Radiopharmaceuticals
2014 Phase 1 NCT02167594 United States;
Flutemetamol
Itoh Yoshiaki
2019 - JPRN-jRCTs051180214 Japan;
Flutemetamol F18
Skane University Hospital
2017 - NCT03174938 Sweden;
Leucine
Washington University School of Medicine
2017 - NCT03545126 United States;
Lithium
Westat
2008 Phase 1/Phase 2 NCT00703677 United Kingdom;United States;
NT 101
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;
Raclopride
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036952 Japan;
TPI 287 2 mg/m2
University of California, San Francisco
2014 Phase 1 NCT02133846 United States;
TPI-287 20 mg/m2
University of California, San Francisco
2014 Phase 1 NCT02133846 United States;
TPI-287 6.3 mg/m2
University of California, San Francisco
2014 Phase 1 NCT02133846 United States;
Vizamyl (flutemetamol(F-18))
Skåne University Hospital
2017 Phase 2 EUCTR2017-000094-36-SE Sweden;
Xeomin
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;
Skåne University Hospital, Region Skåne
2014 - EUCTR2014-000422-38-SE Sweden;
18F-FDG
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036908 Japan;
18F-RO6958948
Skåne University Hospital
2017 Phase 2 EUCTR2017-000094-36-SE Sweden;
ABBV-8E12
AbbVie
2018 - NCT03744546 -
Anti-Parkinson medication
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Apomorphine
Fondation Ophtalmologique Adolphe de Rothschild
2018 - NCT04786158 France;
BIIB092
University of California, San Francisco
2018 Phase 1 NCT03658135 United States;
Brain PET scan
Avid Radiopharmaceuticals
2014 Phase 1 NCT02167594 United States;
Davunetide (AL-108, NAP)
University of California, San Francisco
2010 Phase 1 NCT01056965 United States;
Deep Brain Stimulation
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Dopamine
Juntendo University school of MedicineDepartment of Diagnosis, Prevention and Treatment of Dementia
2014 - JPRN-UMIN000014098 Japan;
Fasudil
Woolsey Pharmaceuticals
2021 Phase 2 NCT04734379 United States;
Flortaucipir F18
Avid Radiopharmaceuticals
2014 Phase 1 NCT02167594 United States;
Flutemetamol
Itoh Yoshiaki
2019 - JPRN-jRCTs051180214 Japan;
Flutemetamol F18
Skane University Hospital
2017 - NCT03174938 Sweden;
Leucine
Washington University School of Medicine
2017 - NCT03545126 United States;
Lithium
Westat
2008 Phase 1/Phase 2 NCT00703677 United Kingdom;United States;
NT 101
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;
Raclopride
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036952 Japan;
TPI 287 2 mg/m2
University of California, San Francisco
2014 Phase 1 NCT02133846 United States;
TPI-287 20 mg/m2
University of California, San Francisco
2014 Phase 1 NCT02133846 United States;
TPI-287 6.3 mg/m2
University of California, San Francisco
2014 Phase 1 NCT02133846 United States;
Vizamyl (flutemetamol(F-18))
Skåne University Hospital
2017 Phase 2 EUCTR2017-000094-36-SE Sweden;
Xeomin
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;